Compass Therapeutics (NASDAQ:CMPX – Get Free Report) is one of 842 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Compass Therapeutics to similar companies based on the strength of its valuation, risk, institutional ownership, dividends, profitability, earnings and analyst recommendations.
Insider and Institutional Ownership
68.4% of Compass Therapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 18.7% of Compass Therapeutics shares are owned by company insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Compass Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Compass Therapeutics | $850,000.00 | -$66.49 million | -1.44 |
| Compass Therapeutics Competitors | $708.28 million | $8.26 million | -18.37 |
Volatility & Risk
Compass Therapeutics has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Comparatively, Compass Therapeutics’ rivals have a beta of -1.85, suggesting that their average share price is 285% less volatile than the S&P 500.
Profitability
This table compares Compass Therapeutics and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Compass Therapeutics | N/A | -49.93% | -43.76% |
| Compass Therapeutics Competitors | -12,516.26% | -215.37% | -31.41% |
Analyst Ratings
This is a breakdown of recent recommendations for Compass Therapeutics and its rivals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Compass Therapeutics | 1 | 3 | 12 | 1 | 2.76 |
| Compass Therapeutics Competitors | 9920 | 15335 | 45741 | 1601 | 2.54 |
Compass Therapeutics presently has a consensus price target of $9.99, suggesting a potential upside of 1,372.61%. As a group, “Biotechnology” companies have a potential upside of 110.37%. Given Compass Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Compass Therapeutics is more favorable than its rivals.
Summary
Compass Therapeutics beats its rivals on 10 of the 13 factors compared.
About Compass Therapeutics
Compass Therapeutics is a clinical-stage biotechnology company focused on developing antibody-based medicines for cancer. The company’s research centers on immuno-oncology and other approaches intended to target biological pathways involved in tumor growth and the body’s immune response. One of its investigational programs is CTX-009, a bispecific antibody designed to target DLL4 and VEGF-A, proteins associated with tumor blood-vessel development. Compass is also advancing other antibody programs for potential use against solid tumors.
Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
